Slingshot members are tracking this corporate initiative:
Lilly And Boehringer Ingelheim Announce Clinical Trial Collaboration In Metastatic Breast Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
Lilly's abemaciclib is designed to block the growth of cancer cells by specifically inhibiting CDK 4 and CDK 6. In many cancers, uncontrolled cell growth arises from a loss of control in regulating the cell cycle due to increased signaling from CDK 4 and CDK 6. Boehringer Ingelheim's BI 836845 is an IGF ligand-neutralizing antibody that binds to both IGF-1 and IGF-2 preventing activation of the respective receptor resulting in decreased growth-promoting signaling, which may decrease tumor growth. In a Phase 1b/2 trial BI 836845 has shown promising preliminary efficacy and good clinical safety in combination with everolimus and exemestane in patients with HR+ mBC.1The rationale for the collaboration is based upon the hypothesis that these two agents, in combination, could offer a more complete pathway interference and could potentially prolong cell cycle arrest. For HR+, HER2- mBC patients, this could translate to a reversal of resistance to hormone therapy.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Jul 13, 2016 Projected Implementation: Q3, 2016 Relevance Tracked Until: Q2, 2017
Don’t see a project related to the strategic initiative you care about?
Related Keywords Metastatic Breast Cancer, Igf Mab Bi 836845, Insulin-like Growth Factor, Cyclin-dependent Kinase, Cdk 6 Inhibitor, Breast Cancer, Abemaciclib, Bi 836845